Once we really focused our trials on the right subgroup, then it was a question of really finding patients with the right level of disease activity. And, um, you don't want just the regular person who walks around and has a little bit of cough. I mean, uh, the risk factors for, for progression and for hospitalization and for poor quality of life and, uh, for death due, due to bronchiectatic flares. I mean, They are, um, they've been well delineated. Um, the bronchiectasis severity index, um, developed by James Chalmers and his colleagues in Europe, can be a useful tool guide as a predictive tool guide. But the bottom line is there, there's a couple of things. One, you know, how many flare-ups. Exacerbations does a patient have per year. If they're in the 2 to 3 or more per year range, they are more severe and more likely to have, um, continued frequent exacerbations in the future. Are they colonized with pseudomonas or perhaps other gram negatives? That is a, um, good risk factor for prediction for, uh, future, um, disease activity and exacerbation. Um, age, for example, there's various other factors, but, These are the kinds of patients that we need to get into trials, so we can measure whether we can actually reduce their frequency of exacerbation. Um, if you enroll milder people who aren't going to exacerbate, of course, it's a lot harder to, to measure a change in their exacerbation rate cause it was so low to begin with. So, if you notice the last few inhaled antibiotic trials and, And then the renzocadeb studies, I mean, we really enrolled those, quote unquote, frequent exacerbators to meet those case criteria of having two or more exacerbations in the last 12 months. Those people tend to have a lot more symptoms, not always. There are people with symptoms who don't exacerbate much, as well as vice versa, but it tends to go along with, It's the same picture, frequent exacerbations, frequently colonized with the right organisms, um, and have, you know, daily symptoms. Uh, so those are the people that we're focused upon in, in the phase two and phase three trials for brunzocaib. Um, Yeah, and certainly those are the people that, you know, I think we're targeting uh for for this drug in daily practice now it's approved, at least that's the highest priority, get it to the people who are potentially gonna benefit the most.
Presenter
